HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lannett To Close And Sell NY Liquids Plant As Part Of Restructuring Plans

Cost Savings Of $20m Annually Targeted; Portfolio Also Rationalized

Executive Summary

Lannett is once again taking the axe to its operations in order to tighten its focus and save on costs, including the planned divestment of its liquids generics manufacturing facility in Carmel, NY.

You may also be interested in...



NYSE Gives Lannett Six Months To Meet Standards

US firm has received a notice of non-compliance from NYSE due to price of company’s shares. Lannett insists there is no immediate impact, but it is evaluating options, including “transactions that are subject to approval of Lannett’s stockholders.”

Lannett: Pricing Pressure ‘Intensified Beyond Historical Norms’

Not many firms report a negative EBITDA when adjusted for costs, but this Lannett's fate during its FY2022 Q2. Management addressed challenges for Lannett’s base business and the ways in which it intends to turn the tide in the coming years.

Lannett Looks To Transform Company With Five Pipeline Assets

With five “large, durable assets” in its pipeline, Lannett is confident that post approval these products have the potential to transform the company. This includes the generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) recently added to Lannett’s respiratory generics portfolio. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS151927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel